BioLineRx Ltd. To Host Investor Breakfast In New York On December 3, 2015

BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, today announced that it will host an investor breakfast on Thursday, December 3, 2015, in New York City.

At the breakfast, the Company will present the clinical development strategy for BL-8040, its lead oncology and hematology platform, for 2016 and beyond. The event will also include a keynote presentation by internationally-renowned key opinion leader, Dr. John DiPersio, Chief of the Division of Oncology at Washington University School of Medicine in St. Louis, entitled a "Review of the CXCR4 Landscape."
Event Schedule:
8:00 a.m. -- 8:35 a.m.     Breakfast and registration
8:35 a.m. -- 9:45 a.m. Presentations
9:45 a.m. -- 10:00 a.m. Q&A
 
Location:
Convene, Bryant Park Hub
730 Third Avenue (between 45th and 46th Street)
New York, NY 10017
Tel: 646-854-7950
 

BioLineRx Ltd. will also host a live audio webcast of the investor breakfast. For access to the webcast, please go to the breakfast event page on BioLineRx's website. It is recommended that users register 15 minutes prior to the scheduled start time to ensure timely connection. An audio replay of the meeting will also be available for approximately three months following the meeting on the breakfast event page.

Registration and Additional Information

Advanced registration is required for onsite attendance. To register, please contact Vivian Cervantes at vivian@pcgadvisory.com.

About BioLineRx

BioLineRx is a publicly-traded, clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates. The Company in-licenses novel compounds primarily from academic institutions and biotech companies based in Israel, develops them through pre-clinical and/or clinical stages, and then partners with pharmaceutical companies for advanced clinical development and/or commercialization.

If you liked this article you might like

BioLineRx (BLRX) Stock Soars on Liver Drug Licensing Agreement

7 Stocks Under $10 to Trade for Big Profits

7 Stocks Under $10 Making Big Moves

BioLineRx (BLRX) Stock Down on Negative Heart Disease Treatment Results

Bioline RX (BLRX) Stock Gains on Positive Test Results, Coverage Initiation